Eliquis Regulatory Post Marketing Surveillance

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: NonValvular Atrial Fibrillation

Treatments: Drug: Apixaban

Study type: Observational

Funder types: Industry

Identifiers

NCT01885598

CV185-259

Details and patient eligibility

About

The primary objective of this study is to examine the safety profile of Eliquis in Korean nonvalvular atrial fibrillation patients.

Enrollment: 3,335 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients ≥19 years of age
• Adult patients who are diagnosed with nonvalvular atrial fibrillation and are initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic embolism
• Patients with evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion Criteria:

• Receiving Eliquis treatment for an indication that is not approved in Korea
• Contraindicated for the use of Eliquis as described in the Korean label

Trial design

3,335 participants in 1 patient group

Nonvalvular Atrial Fibrillation patients with risk of Stroke

Description:

Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release

Treatment:

Drug: Apixaban